P-Cure Ltd

P-Cure Ltd is an Israeli medical device company focused on proton therapy for cancer treatment. It was founded by Michael Marash, Ph.D., who serves as Founder and CEO, with the stated mission of expanding the availability of proton therapy so that more patients can benefit from it. The company positions itself around a patient-first philosophy, arguing that the dominant barrier to proton therapy access is the high capital cost of building conventional proton centers. P-Cure's core offering is a gantry-less proton therapy system that has received FDA clearance. Unlike conventional proton therapy installations built around a large rotating gantry, the P-Cure solution is compact — described by the company as comparable in size to a single-floor linac room, roughly five times smaller than a gantry room, and requiring about 50 percent less shielding. The system is fully integrated with synchrotron-generated pencil beam scanning and allows patients to be treated in seated or supine positions. The company argues that seated treatment improves patient comfort, reduces internal organ motion, and may reduce collateral radiation to sensitive organs, while also improving imaging resolution. Commercially, P-Cure markets its system on cost efficiency. The company claims its solution can reduce the capital cost of a proton center by about 50 percent, enabling wider availability of proton therapy and faster return on investment. It also emphasizes that its systems are adaptive-therapy ready and that a one-room expandable center can be built at roughly half the price of other currently available systems, with even greater savings for a two-room center. The company's tagline, "See P-Cure First," reflects its pitch as the most cost-effective route to establishing proton therapy services. P-Cure's messaging is supported by endorsements from radiation oncology opinion leaders, including Hanne M. Kooy, Ph.D., of Massachusetts General Hospital; Zelig A. Tochner, MD, former Emeritus Professor of Radiation Oncology at the University of Pennsylvania; and William F. Hartsell, MD, Radiation Oncologist and Medical Director at the Chicago Proton Center. These endorsements highlight the adaptive therapy approach, the potential cost reduction of a gantry-less system, and the clinical rationale for the technology. The company operates in the highly specialized radiation oncology equipment market, competing with established proton therapy vendors. Its differentiation rests on compactness, lower capital cost, seated patient positioning, and integration with pencil beam scanning. P-Cure is privately held and, based on available evidence, remains an active developer and marketer of proton therapy systems.

P-Cure Ltd was founded by Michael Marash, Ph.D., who serves as Founder and CEO. The company was established with the goal of expanding the availability of proton therapy and enhancing its benefits for treating and curing cancer. In his account of the company's origins, Marash explains that his intention was to design proton therapy around the patient in a more natural and anatomically correct way, rather than to deliberately "shift the paradigm" of treatment planning and delivery. A central motivation was access: he notes that less than 1 percent of patients who could benefit from proton therapy have access to it, and identifies the capital cost of developing a proton center as the limiting factor. P-Cure's answer to this problem is a gantry-less proton therapy system that has received FDA clearance. The system is designed to fit into linac-like vaults, allowing a proton center to be built without building a conventional proton center. It is compact — comparable in size to a single-floor linac room, about five times smaller than a gantry room, and requiring roughly 50 percent less shielding. The system is fully integrated with synchrotron-generated pencil beam scanning to deliver continuous and precise treatment plans, and it allows patients to be treated in seated or supine positions. The company argues that its approach yields clinical advantages. Seated positioning is presented as offering greater patient comfort, less organ movement, and a potential reduction in collateral radiation to sensitive organs. P-Cure also states that its treatment solution is expected to yield improved dose distribution, exposing healthy tissues and organs to significantly less radiation, and that it aims to reduce the magnitude of internal organ motion while markedly improving imaging resolution. On the commercial side, P-Cure emphasizes cost efficiency. The company claims its solution can reduce the capital costs of a proton center by 50 percent, providing wider availability of proton therapy and faster ROI. It contrasts the cost of conventional centers — stating that a multi-room center of 3 or 4 rooms may cost between $140–$180 million and a one-room center between $40–$50 million — and argues that the proportional cost per treatment vault is approximately the same for large and one-room centers. P-Cure says it has shifted the paradigm by reducing the cost of a one-room expandable center to approximately half the price of any other system currently available, with even greater savings for a two-room center. It also states that its systems are adaptive therapy ready. The company's positioning is captured in its tagline, "See P-Cure First," which it uses to present itself as the solution for the most cost-effective center, with the shortest time for ROI and a more compassionate, effective form of treatment planning and delivery. P-Cure's technology and claims have been endorsed by radiation oncology opinion leaders, including Hanne M. Kooy, Ph.D., Associate Professor of Radiation Oncology at Massachusetts General Hospital, who described adaptive therapy combined with proton beam scanning as a quantum leap in the ability to cure cancer patients with radiation; Zelig A. Tochner, MD, former Emeritus Professor of Radiation Oncology at the University of Pennsylvania, who said P-Cure's gantry-less system can significantly reduce the cost of the initial investment required to establish proton therapy services; and William F. Hartsell, MD, Radiation Oncologist and Medical Director at the Chicago Proton Center. P-Cure is privately held and, based on available evidence, remains an active company marketing its FDA-cleared gantry-less proton therapy system.

• P-Cure founded by Michael Marash, Ph.D., with the mission of expanding access to proton therapy.

• FDA clearance received for the gantry-less proton therapy system.

Cost-effective, compact, patient-first proton therapy that reduces capital costs and improves access.

• Gantry-less proton therapy system

  FDA-cleared proton therapy system that fits into linac-like vaults, is about five times smaller than a gantry room, requires roughly 50 percent less shielding, integrates synchrotron-generated pencil beam scanning, and allows seated or supine patient treatment.

1. 1Homepage | P-CUREp-cure.com
2. 2About us | P-CUREp-cure.com
3. 3P-Cure Ltdwikidata.org